For HIV-1–negative, at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1. See full Indication.

Dosing Schedule and Drug Interactions

APRETUDE must be administered by a healthcare provider (HCP). Prior to prescribing HCP-administered APRETUDE, HCPs should carefully select individuals who agree to the required dosing and testing schedule and counsel patients on the importance of adherence to help reduce the risk of HIV-1 infection and development of resistance.

Dosing and Testing Schedule

Adherence you can confirm with as few as 6 in-office injections per year* 

Starting Your Patients on APRETUDE

Starting Your Patients on Apretude
starting chart

M=month.

APRETUDE injections can be given up to 7 days before or after the scheduled injection date

*After optional oral lead-in and initiation injections.

For patients concomitantly receiving rifabutin, please see the full Prescribing Information for the  adjusted recommended dosing schedule for APRETUDE.

After the first injection.

Optional oral lead-in

Oral lead-in is not required but may be used prior to the initiation of APRETUDE to assess the tolerability of cabotegravir.

after lead in chart

M=month.

The recommended oral lead-in dose is one 30‍-‍mg tablet of cabotegravir daily for approximately 1 month (at least 28 days).
Initiation injections should be administered on the last day of oral lead-in, if used, or within 3 days thereafter.

HIV-1 testing and APRETUDE

  • HIV-1 testing should also occur:
    - When recent exposure to HIV is suspected or clinical symptoms consistent with HIV-1 (eg, fever, fatigue, myalgia, skin rash) are present
    - Upon diagnosis of any other STI

  • If positive HIV-1 status is confirmed, transition to a complete HIV-1 treatment
When a payer covers PrEP, HIV testing should also be covered.​ 1 The payer or your lab can help you understand which tests may be covered and available

FDA=US Food and Drug Administration; PrEP=pre-exposure prophylaxis; STI=sexually transmitted infection. 

Injection Schedule

Use this tool to determine your patient’s APRETUDE injection schedule

You will be able to select a target initiation date and view your patient’s potential schedule, including subsequent injection dates and flexible dosing window

chart

Missed Injections

Continuing APRETUDE after planned missed injections

How much time has passed since your patient’s missed Target Injection Date?

§For oral PrEP durations greater than 2 months, an alternative oral regimen is recommended.

Continuing APRETUDE after unplanned missed injections

How much time has passed since your patient’s missed Target Injection Date?

Drug Interactions

Recommendations are based on either drug interaction trials following oral administration of cabotegravir or predicted interactions due to the expected magnitude of the interaction. This chart includes potentially significant interactions but is not all inclusive.

Drug Interactions Chart Mobile
Drug-drug Interactions Chart

↑ = Increase, ↓ = Decrease, ↔︎ = No Change

Reference:

  1. Dept of Labor, Dept of Health and Human Services (HHS), the Treasury. FAQs About Affordable Care Act Implementation Part 47. July 19, 2021. https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-47.pdf

Reference:

  1. Dept of Labor, Dept of Health and Human Services (HHS), the Treasury. FAQs About Affordable Care Act Implementation Part 47. July 19, 2021. https://www.dol.gov/sites/
    dolgov/files/EBSA/about-
    ebsa/our-activities/resource-
    center/faqs/aca-part-47.pdf

CBTWCNT230021